Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $97,853.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 7,988 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $12.25, for a total transaction of $97,853.00. Following the completion of the transaction, the chief financial officer directly owned 137,987 shares of the company’s stock, valued at $1,690,340.75. This trade represents a 5.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Entrada Therapeutics Trading Up 8.3%

TRDA traded up $0.96 on Friday, reaching $12.58. The stock had a trading volume of 465,481 shares, compared to its average volume of 236,850. The company has a market capitalization of $481.56 million, a price-to-earnings ratio of -3.64 and a beta of -0.12. The firm has a 50-day moving average of $11.01 and a 200-day moving average of $8.64. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $12.93.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.38. The firm had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. Sell-side analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on TRDA. Oppenheimer began coverage on Entrada Therapeutics in a research report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 target price on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.50.

Entrada Therapeutics News Roundup

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $20.00 price target on TRDA, which signals meaningful upside from current levels and likely supported buying interest. HC Wainwright note
• Positive Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate to a smaller loss (from ($1.20) to ($1.12)), a modest improvement that can be read as slightly better near‑term expectations for operating performance. HC Wainwright note
• Neutral Sentiment: Short‑interest data reported a jump claim but shows 0 shares short (short‑interest ratio 0.0 days); this appears to be a data anomaly. If accurate, near‑zero reported short interest reduces downward short‑pressure, but the feed’s inconsistency makes this point uncertain. Short interest report
• Negative Sentiment: HC Wainwright cut several near‑term EPS forecasts (Q2–Q4 2026 and FY2026 lowered; FY2026 moved to ($4.49) from ($4.21)) and trimmed multiple 2026/2027 quarterly EPS views, signaling larger expected losses in the near term. Deteriorating near‑term profitability expectations could pressure the stock if operational or cash‑burn concerns persist. HC Wainwright note

Institutional Trading of Entrada Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its position in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after acquiring an additional 666,287 shares during the period. Citadel Advisors LLC grew its stake in shares of Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after acquiring an additional 235,384 shares during the period. Baker BROS. Advisors LP raised its stake in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares during the period. Qube Research & Technologies Ltd lifted its holdings in Entrada Therapeutics by 115.3% during the third quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock valued at $1,670,000 after purchasing an additional 154,143 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Entrada Therapeutics by 4,767.4% during the third quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock worth $860,000 after purchasing an additional 145,167 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.